VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Pharmaceuticals

Real-time Estimate Cboe BZX 10:36:27 2024-04-12 am EDT 5-day change 1st Jan Change
2.845 USD -5.17% Intraday chart for VYNE Therapeutics Inc. -0.97% +20.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000 MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : VYNE Therapeutics Inc. - Special Call
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday MT
Top Premarket Gainers MT
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo CI
VYNE Therapeutics Inc. announced that it expects to receive $88.151509 million in funding CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $99,000 MT
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions CI
VYNE Therapeutics Inc. Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis CI
Sector Update: Healthcare Stocks Mostly Higher Late Thursday MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon MT
Sector Update: Health Care MT
Vyne Therapeutics Says Vitiligo Drug Candidate Has No Negative Effect on Platelet Count in Phase 1a Trial; Shares Rise MT
Chart VYNE Therapeutics Inc.
More charts
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3 USD
Average target price
5.583 USD
Spread / Average Target
+86.11%
Consensus
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. News VYNE Therapeutics Inc.
  5. Sector Update: Health Care Stocks Mixed Thursday Afternoon